CENTER FOR CANCER BIOLOGY RESEARCH

癌症生物学研究中心

• 批准号: 8359559
• 负责人: W KEITH MISKIMINS
• 金额: $ 225.18万
• 依托单位: SANFORD RESEARCH/USD
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-02 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8359559
• 关键词: Animal Model; Antibodies; Applications Grants; Autoantibodies; B lymphoid malignancy; Basic Science; Cancer Biology; Cellular biology; Centers of Research Excellence; Clinical Research; Core Facility; Detection; Development; Diagnostic tests; Differentiation Antigens; Doctor of Philosophy; Drug Delivery Systems; Faculty; Flow Cytometry; Funding; Goals; Grant; Head and Neck Squamous Cell Carcinoma; Human; Image; Immune response; Immunology; Immunotherapy; Malignant Neoplasms; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Manuscripts; Mediating; Membrane; Mentors; Methods; Molecular Biology; Monoclonal Antibodies; National Center for Research Resources; Pathway interactions; Patients; Postdoctoral Fellow; Preparation; Principal Investigator; Protein Kinase; Proteins; Radioimmunotherapy; Recruitment Activity; Research; Research Design; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Role; Scientist; Series; Serum; Signal Transduction; Source; Students; Surface Antigens; Technology; Testing; Training; Translational Research; Tumor Biology; United States National Institutes of Health; anticancer research; cancer cell; career development; cost; cytotoxic; experience; molecular pathology; nanoparticle; novel; novel diagnostics; programs; tumor; tumor progression

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. DESCRIPTION (provided by applicant): This is a proposal to establish a Center of Biomedical Research Excellence (COBRE) focusing on Cancer Biology with emphasis on the identification, functional characterization, and targeting of tumor specific markers and antigens. Our center will use cell and molecular biology, immunology, nanoparticle technology, and animal models to examine the development, detection, and treatment of human cancer. Five research projects are included. The goals of Project 1 (Meena Jaggi, PhD) are to understand the effects of protein kinase Dl on (3- catenin-mediated signaling and to determine if PKDl expression influences tumor progression through this pathway. For Project 2 (Kristi Egland, PhD) a large number of membrane and secreted proteins that are expressed at elevated levels in prostate cancer cells were identified. This information will be used to develop a new diagnostic test for prostate cancer that detects autoantibodies in patient serum. Project 3 (Satoshi Nagata, PhD) will develop a panel of monoclonal antibodies to surface antigens that are highly expressed in B cell malignancies. These antibodies will be tested for their potential use in immunotherapies. Project 4 (Subhash Chauhan, PhD) will develop novel methods of treatment and drug delivery for pancreatic cancer. The goal will be to combine radioimmunotherapy and nanoparticle technology for highly specific delivery of cytotoxic compounds. Project 5 (William Spanos, MD) will focus on the role of the immune response in tumor clearance following treatment of head and neck squamous cell carcinoma. A strong mentoring plan will take advantage of the experience of an outstanding group of senior faculty with active research programs. Mentors will provide guidance for research design, manuscript preparation, grant applications, and other crucial aspects of career development. An EAC consisting of five internationally recognized scientists with broad experience in basic, translational, and clinical research has been assembled. Research capabilities will be supported by core facilities in Molecular Pathology, Flow Cytometry, Tumor Biology, and Imaging. We v"ll recruit 3 high quality junior investigators and 1 established investigator. We will train students and post-doctoral fellows, support a seminar series, and fund pilot research projects in the field of cancer research.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 描述(由申请人提供)：这是一个建议建立一个生物医学研究卓越中心(COBRE)，专注于癌症生物学，重点是肿瘤特异性标志物和抗原的识别、功能表征和靶向。我们的中心将使用细胞和分子生物学、免疫学、纳米颗粒技术和动物模型来研究人类癌症的发展、检测和治疗。包括五个研究项目。项目1(Meena Jaggi，PhD)的目标是了解蛋白激酶DL在(3-连环蛋白介导的信号转导)中的作用，并确定PKD1的表达是否通过这一途径影响肿瘤的进展。在项目2(Kristi Egland，PhD)中，发现了大量在前列腺癌细胞中高水平表达的膜蛋白和分泌蛋白。这些信息将被用于开发一种新的前列腺癌诊断测试，该测试可以检测患者血清中的自身抗体。项目3(Satoshi Nagata，PhD)将开发一组针对B细胞恶性肿瘤中高度表达的表面抗原的单抗。这些抗体将被测试它们在免疫疗法中的潜在用途。项目4(Subhash Chauhan，PhD)将开发治疗胰腺癌和给药的新方法。其目标将是将放射免疫疗法和纳米颗粒技术相结合，以实现高度特异性的细胞毒性化合物输送。项目5(医学博士威廉·斯潘诺斯)将专注于头颈部鳞状细胞癌治疗后免疫反应在肿瘤清除中的作用。一个强有力的指导计划将利用一批优秀的资深教员的经验，他们拥有积极的研究计划。导师将为研究设计、手稿准备、拨款申请和职业发展的其他关键方面提供指导。由五名在基础、翻译和临床研究方面具有广泛经验的国际公认的科学家组成的EAC已经组建完毕。研究能力将得到分子病理学、流式细胞术、肿瘤生物学和成像方面的核心设施的支持。我们将招聘3名高素质的初级研究员和1名资深研究员。我们将培养学生和博士后研究员，支持一系列研讨会，并资助癌症研究领域的先导性研究项目。